Igenica Raises $33M For Cancer Antibodies
Burlingame-based Igenica, a developer of biopharmaceuticals focused on the cancer market, has raised $33M in a Series C funding round. The round was led by Third Rock Ventures, and also included The Column Group, Orbimed Advisors and 5AM Ventures. According to the company, the funding brings its total raised to $55M. The funding will go towards clinical trials of its products, which are antibody-based cancer medicines.
posted on Tuesday, June 12, 2012 (Link to more information)
Related companies:
IGENICA INC
Related stories:
> Forty Seven Finds $32.5M For Cancer Antibodies
> KaloBios Pharmaceuticals Raises $12M
> Jennerex Raises $8.3M
> Forty Seven Finds $75M For Cancer Drugs
> MedGenome Raises $30M
silicontap.com Home